Scribe’s early-stage IPO standout defies biotech’s derisking trend
Scribe Therapeutics’ one-time epigenetic treatment is designed to slash the adherence burden of chronic cholesterol-lowering therapies while sidestepping the irreversibility of gene editing.
Scribe’s early-stage IPO standout defies biotech’s derisking trend Read More »
